2023 World Conference on Lung Cancer (Posters)-EP12.01. A Case of Long PFS by Aumolertinib in Advanced Lung Cancer with Multiple Metastases lncluding Brain Metastasis

EP12.01. A Case of Long PFS by Aumolertinib in Advanced Lung Cancer with Multiple Metastases lncluding Brain Metastasis - PDF(Slides)

Back to course

Pdf Summary

This case report discusses a successful treatment strategy for a patient with advanced lung adenocarcinoma and multiple metastases, including brain metastasis. The current guidelines recommend EGFR-TKIs as the first choice for this type of cancer, but patients with brain metastasis have limited benefits and a shorter progression-free survival (PFS). However, a study on the third-generation EGFR-TKI has shown a median PFS of 15.3 months in Chinese patients with brain metastasis. The challenge lies in optimizing the treatment strategy for patients with multiple metastases in addition to brain metastasis.<br /><br />In this case, a 63-year-old female with left lung adenocarcinoma (stage IV), mediastinal lymph node metastasis, brain metastasis, bone metastasis, bilateral pulmonary metastasis, and EGFR L858R mutation was treated with osimertinib for one month, which resulted in a continuous partial response. However, due to economic reasons and the high permeability of the blood-brain barrier, the treatment was changed to aumolertinib, which significantly improved the pain in the patient's left foot. The patient continued to have a close follow-up with no obvious adverse reactions. The progression-free survival was 2 years and 8 months.<br /><br />The case presentation includes mutation variation analysis on lung tumor tissues, as well as radiographic follow-up with brain MRI, chest and abdomen CT, and whole-body PET-CT. The response was measured using the Response Criteria in Solid Tumors (RECIST) 1.1 Criteria.<br /><br />In conclusion, aumolertinib monotherapy brought positive outcomes for advanced lung adenocarcinoma patients with multiple metastases, including brain metastasis. It demonstrated efficacy and safety, and the rapid effect of EGFR-TKI treatment allowed for a delayed timing of local treatment for brain and bone metastases, improving the patient's quality of life.

Asset Subtitle

Xiu Shan

Meta Tag

Speaker Xiu Shan

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

lung adenocarcinoma

metastasis

brain metastasis

EGFR-TKI

progression-free survival

third-generation EGFR-TKI

osimertinib

aumolertinib

blood-brain barrier

mutation variation analysis